An Open Label Study Evaluating the Efficacy and Safety of AB928 Based Treatment Combinations in Patients With Metastatic Colorectal Cancer.
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Metastatic Colorectal Cancer
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Single (Outcomes Assessor)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
This is a multicenter, open-label Phase 1b/2 study in participants with metastatic colorectal cancer that will assess the efficacy of etrumadenant. Approximately 250 participants will be enrolled to 1 of 3 cohorts: Cohort A) etrumadenant + zimberelimab +mFOLFOX-6 +/-bev vs mFOLFOX-6 +/-Bev Cohort B)...
This is a multicenter, open-label Phase 1b/2 study in participants with metastatic colorectal cancer that will assess the efficacy of etrumadenant. Approximately 250 participants will be enrolled to 1 of 3 cohorts: Cohort A) etrumadenant + zimberelimab +mFOLFOX-6 +/-bev vs mFOLFOX-6 +/-Bev Cohort B) etrumadenant + zimberelimab +mFOLFOX-6 +/-bev vs regorafenib Cohort C) chemotherapy-free combinations of etrumadenant + zimberelimab + other agents The primary objective of this clinical study is to evaluate the safety of etrumadenant-based combination therapy in participants with metastatic colorectal cancer.
Tracking Information
- NCT #
- NCT04660812
- Collaborators
- Not Provided
- Investigators
- Not Provided
Get Well Soon